1.	Phase I/II Study of Tumor Cell Line Vaccine in Patients With HER2/neu-Positive Breast Cancer, HER2/neu-Negative Breast Cancer, or other HER2/neu-Positive Solid Tumors. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Treatment Status: Temporarily closed Age: 18 and over Sponsor: Other Protocol IDs: WRI-GEV-007, NCT00095862, WRI-GEV-007
2.	Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: J0885 CDR0000634155, P30CA006973, JHOC-NA_00021048, JHOC-J0885, NA_00021048, NCT00847171
3.	Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: J0085 CDR0000391826, R01CA093714, P30CA006973, JHOC-J0085, JHOC-RPN-01012502, JHOC-RAC-0304-578, NCT00093834